Top memory chip supplier denies cancer allegations

Is working on the production line for the world's largest memory chip supplier hazardous to your health?

Since 1997, at least 22 such workers at Samsung Electronics in South Korea have been diagnosed with cancers, including many lymphomas. 10 have died.

Family members and their supporters say that factory conditions are to blame, arguing that the environment is unsafe due to carcinogenic factors such as radiation exposure.

Company executives disagree, claiming that there is no evidence to support the allegations and that safeguards protect employees from such exposure. A pair of recent epidemiological studies carried out by the Korea Occupational Safety & Health Agency would seem to support this. Nonetheless, the Korea Herald is reporting that Samsung will open an investigation into the allegations.

Samsung began manufacturing semiconductors in 1983. Today the company is the largest memory chip maker in the world, supplying chips for many popular devices, such as Apple's iPhone.

By Ross Bonander

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap